Cargando…

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations

Prostate cancer is one of the most common types of cancer worldwide and has strong genetic associations. This is important for the development of therapeutics for the condition, as metastatic castrate-resistant prostate cancer (mCRPC) is resistant to standard androgen deprivation therapy (ADT) and h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Maximillian S, Goldberg, Hanan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675324/ https://www.ncbi.nlm.nih.gov/pubmed/36411744 http://dx.doi.org/10.2147/CMAR.S353411

Ejemplares similares

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Emerging treatment options for ovarian cancer: focus on rucaparib
por: Mariappan, Lavanya, et al.
Publicado: (2017)

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
por: Pearre, Diana C, et al.
Publicado: (2018)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
por: Dal Molin, Graziela Z., et al.
Publicado: (2018)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
por: Labadie, Brian W, et al.
Publicado: (2022)

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
por: Yubero, Alfonso, et al.
Publicado: (2022)

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
por: Dockery, LE, et al.
Publicado: (2017)

The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
por: Curtin, Nicola J
Publicado: (2020)

Evaluation of phototoxicity induced by the anticancer drug rucaparib
por: Mateos-Pujante, Alejandro, et al.
Publicado: (2022)

Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity
por: Wang, Xian, et al.
Publicado: (2018)

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
por: Cohen, Fred, et al.
Publicado: (2022)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration
por: Sautois, Brieuc, et al.
Publicado: (2022)

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
por: Swisher, Elizabeth M., et al.
Publicado: (2021)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
por: Saravi, Sayeh, et al.
Publicado: (2021)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
por: Tookman, Laura, et al.
Publicado: (2020)

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
por: Fizazi, Karim, et al.
Publicado: (2022)

Geriatric considerations in the treatment of advanced prostate cancer
por: Kessler, Elizabeth R., et al.
Publicado: (2014)

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
por: Grechko, Nikolay, et al.
Publicado: (2021)

Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
por: Monk, Bradley J, et al.
Publicado: (2021)

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
por: Guy, Holly, et al.
Publicado: (2018)

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
por: Lorusso, Domenica, et al.
Publicado: (2020)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
por: Zhang, Qilin, et al.
Publicado: (2023)

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
por: Shah, Sidrah, et al.
Publicado: (2021)

Association of TP53 clonal hematopoiesis with indeterminate potential with the development of myeloid neoplasms after rucaparib treatment
por: Yoshida, Reiko, et al.
Publicado: (2022)

Correction: Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
por: Gulley, James L., et al.
Publicado: (2015)

Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
por: Harold, Justin A., et al.
Publicado: (2018)

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
por: Wallace, Katrine, et al.
Publicado: (2019)

A cyanide-catalyzed imino-Stetter reaction enables the concise total syntheses of rucaparib
por: Park, Jinjae, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7v6pkr0t756215jd0ut6geikj6